Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Akamai Technologies, Inc. (AKAM) vs ClearPoint Neuro Inc (CLPT) Price & Performance

Akamai Technologies, Inc.Trade
ClearPoint Neuro IncTrade

Price performance (Past 24H)

Key statistics

Akamai Technologies, Inc. vs ClearPoint Neuro Inc — how do they compare? Akamai Technologies, Inc. trades at $122.5 (market cap $16.77B), while ClearPoint Neuro Inc trades at $15.2 (market cap $454.21M). The key difference: Akamai Technologies, Inc. is far larger — about 36.9× ClearPoint Neuro Inc's market cap, and Akamai Technologies, Inc. is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.

AKAMCLPT
Market Cap
$16.77B$454.21M
Sector
TechnologyHealth
52-Week High
$161.14$29.60
52-Week Low
$71.97$8.66
Enterprise Value
$22.75B$488.79M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Akamai Technologies, Inc.

Akamai Technologies (AKAM) trades at $122.67, up 4.27% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains solid fundamentals with $4.21B revenue and 57.45% gross margins. Recent analyst upgrades and a $600M cloud contract highlight growth potential in AI and cybersecurity services.

Outlook remains cautiously optimistic with a $150.11 consensus price target offering 22% upside, though margin compression and competitive pressures present risks. Institutional sentiment leans neutral with 49% hold ratings, requiring monitoring of Q3 earnings execution and infrastructure investment returns.

ClearPoint Neuro Inc

ClearPoint Neuro (CLPT) trades at $15.18, up 4.19% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth but missed earnings expectations with a $0.38 loss per share. Despite negative profitability metrics, analyst consensus remains unanimously bullish with 100% buy ratings. Recent news highlights regulatory progress with partners and expansion of the drug delivery ecosystem.

The stock presents a high-risk opportunity with strong analyst support despite current losses. Investment thesis hinges on successful commercialization of neuro drug delivery technologies and partnership execution. Key risks include persistent negative cash flow from operations and delayed revenue ramp-up from new facilities. Upside depends on translating regulatory momentum into sustainable revenue growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Akamai Technologies, Inc.

Akamai operates a content delivery network, or CDN, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,000 points of presence in more than 1,000 cities worldwide. Its customers generally include media companies, which stream video content or make video games available for download, and other enterprises that run interactive or high-traffic websites, such as e-commerce firms and financial institutions. Akamai also has a significant security business, which is integrated with its core web and media businesses to protect its customers from cyberthreats.

Read more on AKAM

About ClearPoint Neuro Inc

ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.

Read more on CLPT